Female sexual interest drug reaches tipping point with Phase III plans
Pharmaceutical Technology
OCTOBER 10, 2022
After more than a decade in development, Freya Pharma Solutions plans to advance an oral tablet dubbed Lybrido into Phase III trials to treat female sexual interest/arousal disorder (FSIAD). One Phase II trial was completed back in 2013, as per ClinicalTrials.gov. Emotional Brain worked on these two tablets for much of the past decade.
59 
Let's personalize your content